Beclometasone: 4 agencies, 2005–2024
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
The file has been open for more than a decade: 19.4 years separate the first record, 9 Feb 2005 at AWMSG (Wales), from the most recent, 2024 at PBAC (Australia).
SMC (Scotland) changed its position: recommended on 7 Aug 2006, not recommended by 10 Sep 2007.
No assessment is on file from PHARMAC (New Zealand), TLV (Sweden), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Not every gap is a refusal: for beclometasone, 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 3 of 23 records date from 2023 or later.
5 distinct indication wordings are recorded for beclometasone by the agencies that label one in English (AWMSG, PBAC and SMC).
3 of these 23 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess beclometasone, on 9 Feb 2005; PBAC (Australia) did not open a file until 2020 — an unusually long tail of 15.4 years between the earliest and latest system to look at it.
The record arrives in waves: 7 separate years each carry two or more decisions, spread across 13 years in total.
4 of the 4 agencies here assessed beclometasone more than once, HAS (France) most often at 15 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 4 of the 18 agencies here have assessed beclometasone.
The full ledger for beclometasone reads 13 recommended, 5 other, 3 not assessed and 1 withdrawn, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2024 | Asthma | Recommended | source |
| AWMSG (Wales) | 4 Jul 2023 | For the prophylactic management of mild, moderate, or severe asthma in adults or children: Mild asthma: Patients requiri… | outside AWMSG criteria | source |
| HAS (France) | 1 Apr 2020 | Change to listing conditions (Transparency Committee) | SMR substantial · ASMR V | source |
| HAS (France) | 19 Mar 2014 | Listing (Transparency Committee) | ASMR V | source |
| SMC (Scotland) | 10 Sep 2007 | mild to moderate ulcerative colitis | not recommended | source |
18 further decisions for beclometasone, across 4 agencies, are not shown here. They link to 12 further source documents.
Related molecules
- roflumilast — divergent outcome (recommended vs not recommended) on a shared indication
- budesonide — same ATC class A07E — Antidiarrheals / intestinal anti-inflammatories
- mesalazine — same ATC class A07E — Antidiarrheals / intestinal anti-inflammatories
- beclometasone / formoterol — same ATC class A07E — Antidiarrheals / intestinal anti-inflammatories
- beclometasone / formoterol / glycopyrronium — same ATC class A07E — Antidiarrheals / intestinal anti-inflammatories
- prednisolone — same ATC class A07E — Antidiarrheals / intestinal anti-inflammatories
Coverage: 23 decisions for beclometasone from 4 agencies, 2005 to 2024. Data to 7 Sep 2026. ATC class A07E — Antidiarrheals / intestinal anti-inflammatories. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.